Literature DB >> 15222000

Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.

Cordelia Luyken1, Ingmar Blümcke, Rolf Fimmers, Horst Urbach, Otmar D Wiestler, Johannes Schramm.   

Abstract

BACKGROUND: Supratentorial gangliogliomas (GGs) are rare tumors of the central nervous system and are commonly associated with chronic seizures. To date, only case reports and small series of patients with short-term follow-up have been available for the assessment of the potential of GGs to recur and progress.
METHODS: Data from 184 patients who underwent resection of GGs between 1988 and 2001 were available from the University of Bonn Epilepsy Surgery Center (Bonn, Germany). Analysis of factors that influenced tumor recurrence and patient survival, such as preoperative history, age at operation, tumor location, histopathologic findings (including immunohistochemical findings), extent of tumor resection, and recurrence evaluated on postoperative magnetic resonance imaging (MRI), was performed.
RESULTS: The median follow-up period was 8 years (range, 1-14 years). One hundred seventy-eight patients (97%) presented with long-term seizures (> or = 2 years). The median age at surgery was 26 years (range, 2-65 years). Tumor location was temporal in 79% of patients and frontal in 12% of patients. Eleven tumors (6%) were classified as World Health Organization (WHO) Grade 2 lesions, and 2 tumors were classified as anaplastic WHO Grade 3 lesions. For 38 patients (21%), postoperative MRIs revealed residual tumors. Two years after surgery, 5 patients (3%) experienced tumor recurrence, which resulted in malignant progression in 3 patients (2%) and death in 2 patients (1%). Eighty-four percent of patients with epilepsy had complete and sustained seizure relief. The calculated 7.5-year recurrence-free survival rate was 97%. Lower rates of recurrence were found in patients with tumors classified as WHO Grade 1 lesions (P < 0.0001), patients with temporal lesions (P < 0.0001), patients who underwent complete tumor resection (P = 0.0278), and patients with long-standing epilepsy (P < 0.0001).
CONCLUSIONS: Supratentorial GGs are benign tumors, and the surgical goal for patients with GG should be complete resection. Residual tumor masses, frontal tumor location, and WHO Grade 2 or 3 lesions are associated with a greater risk of recurrence or malignant progression. Patients with such characteristics should be considered for long-term clinical follow-up using MRI. . Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 15222000     DOI: 10.1002/cncr.20332

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  55 in total

1.  Neuro-oncology: gangliogliomas--what is the appropriate management strategy?

Authors:  Minesh P Mehta
Journal:  Nat Rev Neurol       Date:  2010-04       Impact factor: 42.937

2.  Optic pathway ganglioglioma with intraventricular cyst.

Authors:  Pietro Spennato; Mario Giordano; Claudio Ruggiero; Ferdinando Aliberti; Maria Consiglio Buonocore; Anna Nastro; Vittoria D'Onofrio; Delfina Bifani; Giuseppe Cinalli
Journal:  J Neurooncol       Date:  2010-08-20       Impact factor: 4.130

Review 3.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

4.  Ganglioglioma in children and young adults: single institution experience and review of the literature.

Authors:  Wafik Zaky; Shekhar S Patil; Minjeong Park; Diane Liu; Wei-Lien Wang; Khalida M Wani; Susana Calle; Leena Ketonen; Soumen Khatua
Journal:  J Neurooncol       Date:  2018-06-07       Impact factor: 4.130

5.  Survivin expression in ganglioglioma.

Authors:  Audrey Rousseau; Michèle Kujas; Anne-Marie Bergemer-Fouquet; Rémy van Effenterre; Jean-Jacques Hauw
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

Review 6.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

7.  Intracranial ganglioglioma WHO I: results in a series of eight patients treated with stereotactic interstitial brachytherapy.

Authors:  Faycal El Majdoub; Essam Rezk; Stefan Hunsche; Christian Bührle; Volker Sturm; Mohammad Maarouf
Journal:  J Neurooncol       Date:  2014-04-27       Impact factor: 4.130

Review 8.  Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Authors:  Roberta Rudà; Lorenzo Bello; Hugues Duffau; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  SNAI2/Slug promotes growth and invasion in human gliomas.

Authors:  Hong Wei Yang; Lata G Menon; Peter M Black; Rona S Carroll; Mark D Johnson
Journal:  BMC Cancer       Date:  2010-06-17       Impact factor: 4.430

10.  Anaplastic ganglioglioma in children.

Authors:  Michael Karremann; Torsten Pietsch; Gisela Janssen; Christof M Kramm; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2008-11-29       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.